DK1667967T3 - Fremgangsmåde til fremstilling af 2-oxo-1-pyrrolidin-derivater - Google Patents

Fremgangsmåde til fremstilling af 2-oxo-1-pyrrolidin-derivater

Info

Publication number
DK1667967T3
DK1667967T3 DK04765134.4T DK04765134T DK1667967T3 DK 1667967 T3 DK1667967 T3 DK 1667967T3 DK 04765134 T DK04765134 T DK 04765134T DK 1667967 T3 DK1667967 T3 DK 1667967T3
Authority
DK
Denmark
Prior art keywords
oxo
preparation
pyrrolidine derivatives
pyrrolidine
derivatives
Prior art date
Application number
DK04765134.4T
Other languages
English (en)
Inventor
John Surtees
Ousmane Diouf
Francoise Lurquin
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Application granted granted Critical
Publication of DK1667967T3 publication Critical patent/DK1667967T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/267—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom
DK04765134.4T 2003-09-24 2004-09-13 Fremgangsmåde til fremstilling af 2-oxo-1-pyrrolidin-derivater DK1667967T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03021534 2003-09-24
PCT/EP2004/010212 WO2005028435A1 (en) 2003-09-24 2004-09-13 Process for preparing 2-oxo-1-pyrrolidine derivatives

Publications (1)

Publication Number Publication Date
DK1667967T3 true DK1667967T3 (da) 2012-10-08

Family

ID=34354424

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04765134.4T DK1667967T3 (da) 2003-09-24 2004-09-13 Fremgangsmåde til fremstilling af 2-oxo-1-pyrrolidin-derivater

Country Status (15)

Country Link
US (1) US7629474B2 (da)
EP (1) EP1667967B1 (da)
JP (1) JP4658937B2 (da)
KR (1) KR101124098B1 (da)
CN (1) CN1882535B (da)
BR (1) BRPI0414436A (da)
CA (1) CA2538938C (da)
DK (1) DK1667967T3 (da)
EA (1) EA010306B1 (da)
ES (1) ES2390455T3 (da)
HK (1) HK1094702A1 (da)
IL (1) IL174029A (da)
PL (1) PL1667967T3 (da)
WO (1) WO2005028435A1 (da)
ZA (1) ZA200601970B (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006103696A2 (en) * 2005-04-01 2006-10-05 Rubamin Laboratories Limited Process for preparing levetiracetam and racemization of (r)- and (s)-2-amino butynamide and the corresponding acid derivatives
EA016518B1 (ru) * 2005-09-15 2012-05-30 Юсб Фарма, С.А. 4-замещенные пирролидин-2-оны и их применение
EP1993998B1 (en) * 2005-12-07 2013-08-21 UCB Pharma, S.A. 3-carboxy- 2-oxo-1 -pyrrolidine derivatives and their uses
WO2016075082A1 (en) 2014-11-10 2016-05-19 Sandoz Ag Stereoselective reductive amination of alpha-chiral aldehydes using omega-transaminases for the synthesis of precursors of pregabalin and brivaracetam
JP6872500B2 (ja) 2015-05-25 2021-05-19 エステベ・キミカ・ソシエダッド・アノニマＥｓｔｅｖｅ Ｑｕｉｍｉｃａ， Ｓ．Ａ． ブリバラセタムを製造する方法
WO2017076737A1 (en) 2015-11-03 2017-05-11 Ucb Biopharma Sprl Continuous process for preparing brivaracetam
PL3371150T3 (pl) 2015-11-03 2022-01-17 UCB Biopharma SRL Sposób wytwarzania briwaracetamu
CN105646319B (zh) * 2015-12-30 2018-05-18 佛山市隆信医药科技有限公司 一种布瓦西坦的制备方法
CN107513031B (zh) * 2016-06-16 2022-08-02 上海医药集团股份有限公司 一种2-氧代-1-吡咯烷手性衍生物的制备方法
CN108218757A (zh) * 2016-12-14 2018-06-29 上海医药集团股份有限公司 对2-(4-丙基吡咯烷-2-酮)-丁酰胺非对映异构体的拆分方法
CN106748950B (zh) * 2017-01-13 2019-09-03 成都美域高制药有限公司 一种布瓦西坦及其中间体的制备方法
CN108658831B (zh) * 2017-03-30 2021-11-05 江苏豪森药业集团有限公司 2-氧代-1-吡咯烷衍生物或其盐的制备方法
CN107793342A (zh) * 2017-10-19 2018-03-13 丽珠集团新北江制药股份有限公司 一种布瓦西坦的制备方法
CN108548873A (zh) * 2018-03-20 2018-09-18 丽珠集团新北江制药股份有限公司 一种布瓦西坦中间体异构体的检测方法
CN108929289B (zh) * 2018-06-19 2022-01-04 上海博氏医药科技有限公司 一种用于制备布瓦西坦的中间体化合物及其制备方法和用途
CN110615744B (zh) * 2018-06-20 2023-01-06 上海朴颐化学科技有限公司 一种布瓦西坦中间体及其制备方法
CN111333563B (zh) 2018-12-19 2023-11-07 上海科胜药物研发有限公司 一种布瓦西坦中间体的制备方法
CN111892526A (zh) * 2019-05-06 2020-11-06 北京万全德众医药生物技术有限公司 一种布瓦西坦的新制备方法
EP4144724A4 (en) 2020-04-30 2023-03-15 Shanghai Syncores Technologies Inc. Ltd. BRIVARACETAM AND PROCESS FOR MAKING AN INTERMEDIATE THEREOF
WO2023100110A1 (en) 2021-12-02 2023-06-08 Macfarlan Smith Limited Process for preparing brivaracetam

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8412357D0 (en) * 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
GB8827389D0 (en) * 1988-11-23 1988-12-29 Ucb Sa Process for preparation of(s)alpha-ethyl-2-oxo-1-pyrrolidineacetamide
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US20040092575A1 (en) * 2001-03-22 2004-05-13 Jacques Peuvot Use of certain substituted pyrrolidones such as piracetam in the treatment of viral and other diseases
EP1395560A1 (en) 2001-05-23 2004-03-10 Ucb, S.A. 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders
ATE410412T1 (de) * 2001-08-10 2008-10-15 Ucb Pharma Sa Oxopyrrolidin verbindungen, verfahren zur herstellung dieser verbindungen und deren verwendung zur herstellung von levetiracetam und analogen

Also Published As

Publication number Publication date
JP2007515387A (ja) 2007-06-14
EP1667967A1 (en) 2006-06-14
EP1667967B1 (en) 2012-08-01
CA2538938C (en) 2011-08-09
BRPI0414436A (pt) 2006-11-14
AU2004274157A1 (en) 2005-03-31
EA010306B1 (ru) 2008-08-29
ZA200601970B (en) 2007-05-30
KR20060121889A (ko) 2006-11-29
EA200600485A1 (ru) 2007-02-27
KR101124098B1 (ko) 2012-03-21
US7629474B2 (en) 2009-12-08
CN1882535B (zh) 2011-05-11
US20070100150A1 (en) 2007-05-03
ES2390455T3 (es) 2012-11-13
PL1667967T3 (pl) 2012-11-30
HK1094702A1 (da) 2007-04-04
WO2005028435A1 (en) 2005-03-31
CN1882535A (zh) 2006-12-20
IL174029A (en) 2012-06-28
IL174029A0 (en) 2006-08-01
CA2538938A1 (en) 2005-03-31
JP4658937B2 (ja) 2011-03-23

Similar Documents

Publication Publication Date Title
DK1828164T3 (da) Fremgangsmåde til fremstilling af N-phenylpyrazol-1-carboxamider
DK1778668T3 (da) Fremgangsmåde til fremstilling af dihydropteridion
DK1667967T3 (da) Fremgangsmåde til fremstilling af 2-oxo-1-pyrrolidin-derivater
DK1756049T3 (da) Fremgangsmåde til fremstilling af 1,4-diphenylazetidinon-derivater
DK1611108T3 (da) Fremgangsmåde til fremstilling af telmisartan
DK1296935T3 (da) Fremgangsmåde til fremstilling af substituerede octanoylamider
DK1309545T3 (da) Fremgangsmåde til fremstilling af alkylarylsulfonater
DK1546122T3 (da) Fremgangsmåde til fremstilling af valsartan
DK1380121T3 (da) Fremgangsmåde til fremstilling af oxazolidinoner
DK1831223T3 (da) Fremgangsmåde til fremstilling af L-biopterin
DK1838683T3 (da) Fremgangsmåde til fremstilling af [1,4,5]-oxadiazepinderivater
DK1407037T3 (da) Fremgangsmåde til fremstilling af tagatose
DK1345939T3 (da) Fremgangsmåde til fremstilling af sulfonamidsubstituerede imidazotriazinoner
NO20044814L (no) Fremgangsmate for fremstilling av combretastaniner
DK1678135T3 (da) Fremgangsm de til fremstilling af n-amino-substituerede hetorocykliske forbindelser
IS7958A (is) Aðferð til að framleiða metýl 2-dífenýlmetýlsúlfínýlasetat
DK1575941T3 (da) Fremgangsmåde til fremstilling af (S)-pantoprazol
DK1456229T3 (da) Fremgangsmåe til fremstilling af echinocandin-derivater
DK1572613T3 (da) Fremgangsmåde til fremstilling af benzophenoner
DK1682541T3 (da) Fremgangsmåde til fremstilling af tiotropiumsalte
DK1656365T3 (da) Fremgangsmåde til fremstilling af enantiomerisk rent mirtazapin
DK1660485T3 (da) Forbedret fremgangsmåde til fremstilling af alpha-polymorfisk eletriptanhydrobromid
DK1511724T3 (da) Fremgangsmåde til fremstilling af thioalkylaminderivater
DK1292586T3 (da) Fremgangsmåde til fremstilling af pyrazolopyrimidinoner
DK1888613T3 (da) Fremgangsmåde til fremstilling af thiophenglycosidderivater